KHẢO SÁT NỒNG ĐỘ HBCRAG Ở BỆNH NHÂN XƠ GAN VÀ UNG THƯ GAN DO VIÊM GAN VIRUS B MẠN TÍNH ĐIỀU TRỊ TẠI BỆNH VIỆN ĐẠI HỌC Y HÀ NỘI

Abstract

A retrospective desciptive study was conducted on 45 patients with cirrhosis and 59 patients with hepatocellular carcinoma (HCC) due to chronic hepatitis B at Hanoi Medical University Hospital between 2022 and 2023 to investigate changes in HBcrAg levels. Results: The median HBcrAg level was 5.70 (IQR, 4.3-7.0) in the cirrhosis group and 6.00 (IQR, 4.3-6.5) in the HCC group. There was no significant difference in the HBcrAg levels between the cirrhosis and HCC groups, nor between HBeAg-positive and HBeAg-negative groups. However, HBcrAg levels were significantly higher in patients with HBV DNA levels above 10⁵ cp/ml compared to those with HBV DNA levels below 10⁵ cp/ml. Initial findings indicated that patients with cirrhosis of class C on Child-Pugh score and HCC of stage D on Barcelona Clinic Liver Cancer (BCLC) staging have the highest HBcrAg levels, though no significance differences were observed between stages of cirrhosis or HCC according to these two classification systems. In addition, no association was identified between the number or size of tumors and HBcrAg levels in HCC patients. Conclusion: HBcrAg levels were elevated in patients with cirrhosis and HCC. Further studies with larger samples sizes and longitudinal monitoring of HBcrAg are necessary to accurately assess its role in patients with chronic hepatitis B, cirrhosis, and HCC